non invasive bladder cancer non invasive urothelial cell carcinoma of the bladder
Conditions
Interventions
The intervention consists of 6 weekly courses of intravesical chemotherapy with
MMC, 40 mg. MMC will be concomitantly given with locoregional 70 MHz microwave
hyperthermia, given for 1 hour at a tem
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with intermediate/ high risk Ta-1 grade 3 or Ta-1 grade 2 recurrent or carcinoma in situ (CIS) non-muscle invasive transitional cell carcinoma of the bladder.
Exclusion criteria
Exclusion criteria: *Intravesical (Mitomycin C) MMC during the last 12 months *Bladder tumors other than transitional cel carcinoma *Known allergy to MMC *Small bladder volume; less than 100 cc measured by uroflowmetry *Residual urine > 100 cc measured by ultrasound *A history of muscle invasive carcinoma of the bladder *Urinary incontinence *Hip prosthesis *Pacemaker
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Toxicity will be measured using the Common Toxicity Criteria. With these criteria immunological symptoms, constitutional symptoms and renal/genitourinary symptoms can be categorized. If the treatment has to be delayed two times in a row because of toxicity, treatment will be discontinued | — |
Secondary
| Measure | Time frame |
|---|---|
| Satisfying thermometry with the new bladder catheter | — |
Countries
Netherlands
Outcome results
None listed